logo
Share SHARE
FONT-SIZE Plus   Neg

ChemoCentryx Completes IPO

ChemoCentryx, Inc. (CCXI) said Monday that it has completed its initial public offering of 4.5 million shares of common stock.

In addition, the underwriters of the initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock.

All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share.

J.P. Morgan and Citigroup acted as joint book-running managers of the offering, and Cowen and Company acted as co-manager of the offering.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
If calories are not reduced, exercise alone can have no effect on obesity, says British Sports Medicine, a peer-reviewed journal of sport and exercise medicine. The journal says the blame for expanding waist lines is directly on the type and amount of calories consumed and the poor diet generates more disease than physical inactivity, alcohol and smoking combined. Deutsche Bank (DB) on Sunday reported an about 50 percent decline in first-quarter profit, despite clocking double-digit revenue growth, as the German lender recorded hefty legal charges over allegations of rate-rigging. Casino operator Wynn Resorts said its shareholders ousted Elaine Wynn from the board, reflecting fears that her presence may lead to disharmony with the management.
comments powered by Disqus
Follow RTT